Dotmatics

Dotmatics

Dotmatics was founded in 2005 as a spinout from a UK research lab, built to wrangle the chaotic, multi-format data that bench scientists generate. The platform's early traction came from replacing paper lab notebooks and fragmented legacy systems in biotech and pharmaceutical R&D departments. By 2021, Insight Partners had acquired the business, and in 2023 it was merged with Insight's GraphPad Software to create a combined entity under the Dotmatics brand, then immediately backed again by a $760 million equity investment coordinated by Insight and Sixth Street (per the firm, November 2023). The firm's strategy centers on selling a unified, cloud-based scientific R&D platform — electronic lab notebook, laboratory information management, cheminformatics, and data visualization — into the preclinical and clinical development workflow. The customer base spans large pharma, biotech, chemicals, and academic research. The platform has been deployed across North America, Europe, and parts of Asia-Pacific. In 2024, Dotmatics launched a generative AI search layer called Luma that lets scientists query their entire institutional experimental history in natural language, positioning itself against internal build efforts and rival Benchling (per Dotmatics press release, September 2024). The company operates from Boston and London and has a professional team well into the hundreds, though precise headcount is not publicly fixed. The 2023 recapitalization — one of the larger private equity rounds in life-sciences software that year — was used in part to fund the strategic acquisitions of Cellari, an AI-based image analysis tool, and to expand the GraphPad integration. The combined entity serves over 2 million scientists globally, claiming all of the top 20 pharmaceutical companies as accounts (per the firm's official communications, 2024). What distinguishes Dotmatics structurally is its position as a neutral data fabric beneath the LLM wave: it does not compete with drug companies' own AI models but provides the cleaned, connected scientific data those models require. This has made the firm a consolidator in a fragmented informatics market while it remains privately held, backed by a sector-specialist sponsor with a long hold strategy.